[{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Inceptua Group","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"LUXEMBOURG","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Ocriplasmin","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Oxurion \/ Oxurion ","highestDevelopmentStatusID":"12","companyTruncated":"Oxurion \/ Oxurion "},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Kreos Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Kreos Capital","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Kreos Capital"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Bank Degroof Petercam","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Private Placement","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Bank Degroof Petercam","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Bank Degroof Petercam"},{"orgOrder":0,"company":"Oxurion","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Private Placement","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Undisclosed"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"THR-687","moa":"pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"THR-687","moa":"pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"THR-149","moa":"Plasma kallikrein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Negma Group","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Financing","leadProduct":"THR-149","moa":"PKal","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Negma Group","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Negma Group"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"THR-149","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"THR-149","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"THR-149","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Negma Group","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Termination","leadProduct":"THR-149","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Injection, Extended Release","sponsorNew":"Oxurion \/ Negma Group","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Negma Group"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"THR-149","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Funding","leadProduct":"THR-149","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Oxurion","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"THR-149","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"THR-149","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"VIB","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"THR-149","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.029999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ VIB","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ VIB"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Agreement","leadProduct":"THR-149","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Financing","leadProduct":"THR-149","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxurion \/ Atlas Special Opportunities","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Atlas Special Opportunities"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"THR-149","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ Not Applicable"},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Oxurion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oxurion \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Oxurion

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : Targets are derived from a cutting-edge CRISPR-based platform have successfully confirmed the potential of several of these targets across various relevant in vitro models of Geographic Atrophy.

Brand Name : Undisclosed

Molecule Type : Cell and Gene therapy

Upfront Cash : Not Applicable

May 06, 2024

Lead Product(s) : Undisclosed

Therapeutic Area : Ophthalmology

Highest Development Status : Preclinical

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

02

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : THR-149 is a novel plasma kallikrein (PKal) inhibitor which is being evaluated under phase 2 clinical trials for the treatment of diabetic macular edema (DME).

Brand Name : THR-149

Molecule Type : Peptide

Upfront Cash : Not Applicable

November 20, 2023

Lead Product(s) : THR-149

Therapeutic Area : Ophthalmology

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

03

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : The financing will be used for the development of THR-149, a bicyclic peptide that selectively inhibits human plasma kallikrein, for the treatment of patients with diabetic macular edema.

Brand Name : THR-149

Molecule Type : Peptide

Upfront Cash : Undisclosed

September 18, 2023

Lead Product(s) : THR-149

Therapeutic Area : Ophthalmology

Highest Development Status : Phase II

Sponsor : Atlas Special Opportunities

Deal Size : $3.7 million

Deal Type : Financing

blank

04

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : The financing from the agreement will enable Oxurion to progress the Phase 2, Part B KALAHARI trial of THR-149, a potent PKal inhibitor, in Diabetic Macular Edema (DME).

Brand Name : THR-149

Molecule Type : Peptide

Upfront Cash : Undisclosed

September 11, 2023

Lead Product(s) : THR-149

Therapeutic Area : Ophthalmology

Highest Development Status : Phase II

Sponsor : Atlas Special Opportunities

Deal Size : Undisclosed

Deal Type : Agreement

blank

05

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : The financing will be used for the development of THR-149, a bicyclic peptide that selectively inhibits human plasma kallikrein, for the treatment of patients with diabetic macular edema.

Brand Name : THR-149

Molecule Type : Peptide

Upfront Cash : Undisclosed

August 11, 2023

Lead Product(s) : THR-149

Therapeutic Area : Ophthalmology

Highest Development Status : Phase II

Sponsor : Atlas Special Opportunities

Deal Size : $1.0 million

Deal Type : Financing

blank

06

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : Under the agreement, VIB acquired Oxurion's preclinical oncology asset and will use the upfront in the development of THR-149, being evaluated in a Phase 2 clinical trial as a potential treatment for of diabetic macular edema.

Brand Name : THR-149

Molecule Type : Peptide

Upfront Cash : $0.4 million

July 24, 2023

Lead Product(s) : THR-149

Therapeutic Area : Ophthalmology

Highest Development Status : Phase II

Sponsor : VIB

Deal Size : $32.4 million

Deal Type : Licensing Agreement

blank

07

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : The net proceeds will be used to fund the Phase 2, KALAHARI trial evaluating Oxurion’s THR-149, a bicyclic peptide that selectively inhibits human plasma kallikrein, for treating the up to 50% of patients with diabetic macular edema (DME).

Brand Name : THR-149

Molecule Type : Peptide

Upfront Cash : Undisclosed

June 15, 2023

Lead Product(s) : THR-149

Therapeutic Area : Ophthalmology

Highest Development Status : Phase II

Sponsor : Atlas Special Opportunities

Deal Size : $22.7 million

Deal Type : Financing

blank

08

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : THR-149 is a bicyclic peptide that selectively inhibits human plasma kallikrein (PKal) with an inhibition constant of 0.22 nM. THR-149 is currently being evaluated for Diabetic Macular Edema.

Brand Name : THR-149

Molecule Type : Peptide

Upfront Cash : Not Applicable

June 12, 2023

Lead Product(s) : THR-149

Therapeutic Area : Ophthalmology

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

09

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : THR-149 is a bicyclic peptide that selectively inhibits human plasma kallikrein (PKal) with an inhibition constant of 0.22 nM. Through the inhibition of the kallikrein-kinin system (KKS), THR-149 prevents the induction of retinal vascular permeability an...

Brand Name : THR-149

Molecule Type : Peptide

Upfront Cash : Not Applicable

May 25, 2023

Lead Product(s) : THR-149

Therapeutic Area : Ophthalmology

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

10

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : The financing will be used to progress towards finishing patient recruitment for the Phase 2, Part B KALAHARI trial evaluating Oxurion’s THR-149 for treating the up to 50% of patients with diabetic macular edema (DME).

Brand Name : THR-149

Molecule Type : Peptide

Upfront Cash : Undisclosed

May 22, 2023

Lead Product(s) : THR-149

Therapeutic Area : Ophthalmology

Highest Development Status : Phase II

Sponsor : Atlas Special Opportunities

Deal Size : $22.4 million

Deal Type : Financing

blank